Report Content
Chapter 1 Methodology & Scope
1.1 Industry coverage
1.2 Market scope & definition
1.3 Base estimates & calculations
1.3.1 Data collection
1.4 Forecast parameters
1.5 COVID-19 impact analysis at global level
1.6 Data validation
1.7 Data Sources
1.7.1 Primary
1.7.2 Secondary
1.7.2.1 Paid sources
1.7.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Minimal residual disease testing industry 3600 synopsis, 2018 – 2032
2.2 Business trends
2.3 Regional trends
2.4 Technology trends
2.5 Application trends
2.6 End-use trends
Chapter 3 Minimal Residual Disease Testing Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of cancer
3.2.1.2 Technological advancements
3.2.1.3 Rising investment in R&D activities
3.2.1.4 Diagnostic advantages in minimal residual disease testing
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory policies
3.2.2.2 High cost of minimal residual disease testing
3.3 Growth potential analysis
3.3.1 By technology
3.3.2 By application
3.3.4 By end use
3.4 COVID- 19 impact analysis
3.5 Pricing analysis, 2022
3.6 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.7 Technology landscape
3.8 Reimbursement scenario
3.9 Future market trends
3.10 Gap analysis
3.11 Porter's analysis
3.12 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Company market share analysis, 2022
4.4 Competitive positioning matrix
4.5 Vendor matrix analysis, 2022
4.6 Strategy dashboard, 2022
Chapter 5 Minimal Residual Disease Testing Market Size and Forecast, By Technology (USD Million & Units)
5.1 Key trends, by technology
5.2 Flow-cytometry
5.3 Polymerase chain reaction (PCR)
5.4 Next generation sequencing (NGS)
5.5 Others
Chapter 6 Minimal Residual Disease Testing Market Size and Forecast, By Application (USD Million)
6.1 Key trends, by application
6.2 Lymphoma
6.3 Leukemia
6.4 Solid Tumors
6.5 Others
Chapter 7 Minimal Residual Disease Testing Market Size and Forecast, By End-use (USD Million)
7.1 Key trends, by end-use
7.2 Hospitals
7.3 Specialty clinics
7.4 Diagnostic centers
7.5 Others
Chapter 8 Minimal Residual Disease Testing Market Size and Forecast, By Region (USD Million)
8.1 Key trends, by region
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Poland
8.3.7 Sweden
8.3.8 The Netherlands
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Thailand
8.4.7 Indonesia
8.4.8 Philippines
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Columbia
8.5.5 Chile
8.5.6 Peru
8.6 MEA
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Israel
8.6.5 Turkey
8.6.6 Iran
Chapter 9 Company Profiles
9.1 Adaptive Biotechnologies
9.2 Amgen Inc.
9.3 AstraZeneca
9.4 Bio-Rad Laboratories
9.5 Bio-Techne
9.6 Bristol-Myers Squibb Company
9.7 Exact Sciences Corporation
9.8 Guardant Health
9.9 Invitae
9.10 iRepertoire
9.11 Kite Pharma
9.12 mdxhealth
9.13 Natera, Inc.
9.14 Navidea Biopharmaceuticals
9.15 NeoGenomics Laboratories
9.16 Novartis
9.17 Personalis
9.18 QIAGEN
9.19 Roche
9.20 Sysmex Corporation
9.21 Veracyte, Inc.
